 Adam Wolfe
Concepts (221)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pancreatic Neoplasms | 7 | 2024 | 213 | 4.050 |
Why?
| | Radiation Tolerance | 6 | 2024 | 84 | 2.860 |
Why?
| | Carcinoma, Pancreatic Ductal | 4 | 2024 | 40 | 2.560 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 4 | 2020 | 1031 | 1.350 |
Why?
| | Inflammatory Breast Neoplasms | 3 | 2017 | 4 | 1.120 |
Why?
| | MicroRNAs | 3 | 2024 | 388 | 1.110 |
Why?
| | Cell Line, Tumor | 12 | 2024 | 1436 | 1.090 |
Why?
| | Internship and Residency | 2 | 2024 | 449 | 1.080 |
Why?
| | Proto-Oncogene Proteins B-raf | 3 | 2024 | 80 | 1.070 |
Why?
| | Xenograft Model Antitumor Assays | 5 | 2024 | 222 | 1.040 |
Why?
| | Neoplastic Stem Cells | 3 | 2016 | 93 | 1.000 |
Why?
| | Lipoproteins, HDL | 2 | 2016 | 18 | 0.970 |
Why?
| | Tumor Burden | 3 | 2020 | 136 | 0.960 |
Why?
| | Thyroid Neoplasms | 2 | 2024 | 116 | 0.920 |
Why?
| | CDC2 Protein Kinase | 1 | 2024 | 16 | 0.910 |
Why?
| | Gene Expression Regulation, Neoplastic | 3 | 2024 | 857 | 0.870 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2024 | 69 | 0.860 |
Why?
| | Signal Transduction | 4 | 2024 | 1714 | 0.800 |
Why?
| | DNA-Binding Proteins | 1 | 2024 | 426 | 0.720 |
Why?
| | Isotretinoin | 1 | 2021 | 8 | 0.700 |
Why?
| | Primary Myelofibrosis | 1 | 2021 | 11 | 0.700 |
Why?
| | Dermatologic Agents | 1 | 2021 | 11 | 0.700 |
Why?
| | Acne Vulgaris | 1 | 2021 | 13 | 0.690 |
Why?
| | Pancytopenia | 1 | 2021 | 38 | 0.680 |
Why?
| | Myelodysplastic Syndromes | 1 | 2021 | 86 | 0.670 |
Why?
| | Neoadjuvant Therapy | 2 | 2020 | 125 | 0.650 |
Why?
| | Neutrophils | 1 | 2021 | 148 | 0.640 |
Why?
| | Pharmaceutical Services | 2 | 2017 | 52 | 0.630 |
Why?
| | Fellowships and Scholarships | 1 | 2020 | 127 | 0.630 |
Why?
| | Mutation | 2 | 2024 | 1344 | 0.620 |
Why?
| | Physicians | 1 | 2022 | 241 | 0.620 |
Why?
| | Cell Movement | 2 | 2016 | 276 | 0.590 |
Why?
| | Humans | 29 | 2024 | 52593 | 0.580 |
Why?
| | Melanoma | 1 | 2021 | 279 | 0.580 |
Why?
| | Forkhead Transcription Factors | 2 | 2015 | 121 | 0.570 |
Why?
| | Head and Neck Neoplasms | 2 | 2019 | 287 | 0.570 |
Why?
| | Rhabdoid Tumor | 1 | 2018 | 13 | 0.570 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2016 | 149 | 0.560 |
Why?
| | Macrophages | 2 | 2017 | 379 | 0.540 |
Why?
| | Paracrine Communication | 1 | 2016 | 14 | 0.530 |
Why?
| | Breast Neoplasms | 2 | 2016 | 1205 | 0.530 |
Why?
| | Database Management Systems | 1 | 2017 | 28 | 0.530 |
Why?
| | Technology, Pharmaceutical | 1 | 2016 | 5 | 0.520 |
Why?
| | Automation | 1 | 2016 | 18 | 0.520 |
Why?
| | Simvastatin | 1 | 2015 | 28 | 0.490 |
Why?
| | Pharmacy | 1 | 2016 | 55 | 0.480 |
Why?
| | Interleukin-6 | 1 | 2016 | 277 | 0.470 |
Why?
| | Lipoproteins, VLDL | 1 | 2015 | 9 | 0.470 |
Why?
| | Mice, Nude | 4 | 2024 | 235 | 0.440 |
Why?
| | Delivery of Health Care | 1 | 2016 | 324 | 0.420 |
Why?
| | Animals | 10 | 2024 | 13507 | 0.420 |
Why?
| | Mice | 8 | 2024 | 5958 | 0.420 |
Why?
| | Career Mobility | 2 | 2024 | 31 | 0.420 |
Why?
| | Mice, SCID | 3 | 2020 | 182 | 0.410 |
Why?
| | Faculty, Medical | 2 | 2024 | 91 | 0.390 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2018 | 606 | 0.390 |
Why?
| | Inflammation | 1 | 2016 | 644 | 0.380 |
Why?
| | Female | 16 | 2024 | 28262 | 0.370 |
Why?
| | Neoplasm Recurrence, Local | 3 | 2021 | 643 | 0.360 |
Why?
| | Antineoplastic Agents | 2 | 2016 | 1221 | 0.340 |
Why?
| | Albumins | 2 | 2020 | 32 | 0.340 |
Why?
| | Deoxycytidine | 2 | 2020 | 29 | 0.340 |
Why?
| | Chemotherapy, Adjuvant | 2 | 2020 | 124 | 0.330 |
Why?
| | Paclitaxel | 2 | 2020 | 91 | 0.330 |
Why?
| | Proportional Hazards Models | 2 | 2021 | 444 | 0.320 |
Why?
| | Male | 11 | 2024 | 26863 | 0.300 |
Why?
| | Aged, 80 and over | 4 | 2021 | 3420 | 0.250 |
Why?
| | Thiazoles | 2 | 2024 | 54 | 0.250 |
Why?
| | Prognosis | 2 | 2021 | 2118 | 0.240 |
Why?
| | Cell Proliferation | 3 | 2020 | 1029 | 0.240 |
Why?
| | Retrospective Studies | 3 | 2022 | 6671 | 0.230 |
Why?
| | Middle Aged | 6 | 2021 | 13096 | 0.230 |
Why?
| | Quinolines | 1 | 2024 | 44 | 0.220 |
Why?
| | Caveolae | 1 | 2024 | 6 | 0.220 |
Why?
| | Education | 1 | 2024 | 40 | 0.220 |
Why?
| | ras Proteins | 1 | 2024 | 64 | 0.210 |
Why?
| | Faculty | 2 | 2021 | 74 | 0.210 |
Why?
| | Endocytosis | 1 | 2024 | 55 | 0.210 |
Why?
| | Transfection | 1 | 2024 | 369 | 0.210 |
Why?
| | Hospitals, Community | 1 | 2022 | 20 | 0.200 |
Why?
| | Mentors | 1 | 2022 | 57 | 0.190 |
Why?
| | DNA Damage | 1 | 2024 | 307 | 0.190 |
Why?
| | Neoplasm Staging | 2 | 2021 | 768 | 0.180 |
Why?
| | Cell Cycle | 2 | 2020 | 240 | 0.180 |
Why?
| | Gender Identity | 1 | 2021 | 27 | 0.180 |
Why?
| | Chromosomes, Human, Pair 7 | 1 | 2021 | 30 | 0.170 |
Why?
| | Pediatrics | 1 | 2024 | 295 | 0.170 |
Why?
| | Phosphorylation | 3 | 2017 | 530 | 0.170 |
Why?
| | Lymphatic Metastasis | 1 | 2021 | 211 | 0.170 |
Why?
| | Caveolin 1 | 1 | 2020 | 22 | 0.170 |
Why?
| | Child | 3 | 2022 | 7229 | 0.170 |
Why?
| | Mice, Inbred NOD | 1 | 2020 | 92 | 0.170 |
Why?
| | Leucovorin | 1 | 2020 | 19 | 0.170 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2020 | 64 | 0.170 |
Why?
| | Lymphocytes | 1 | 2021 | 149 | 0.170 |
Why?
| | Spleen | 1 | 2021 | 171 | 0.170 |
Why?
| | Fluorouracil | 1 | 2020 | 59 | 0.170 |
Why?
| | Chromosome Deletion | 1 | 2021 | 141 | 0.160 |
Why?
| | Radiation Dosage | 1 | 2021 | 163 | 0.160 |
Why?
| | Coculture Techniques | 2 | 2017 | 145 | 0.160 |
Why?
| | Drug Administration Schedule | 1 | 2020 | 376 | 0.160 |
Why?
| | Linear Models | 1 | 2020 | 292 | 0.160 |
Why?
| | Survival Rate | 3 | 2019 | 952 | 0.160 |
Why?
| | Radiation-Sensitizing Agents | 1 | 2019 | 52 | 0.150 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2021 | 169 | 0.150 |
Why?
| | DNA Breaks, Double-Stranded | 1 | 2019 | 71 | 0.150 |
Why?
| | Kaplan-Meier Estimate | 1 | 2020 | 485 | 0.150 |
Why?
| | Aged | 3 | 2021 | 10191 | 0.150 |
Why?
| | Tumor Microenvironment | 2 | 2017 | 255 | 0.140 |
Why?
| | Consolidation Chemotherapy | 1 | 2018 | 12 | 0.140 |
Why?
| | Interleukin-13 | 1 | 2017 | 16 | 0.140 |
Why?
| | STAT6 Transcription Factor | 1 | 2017 | 9 | 0.140 |
Why?
| | Curriculum | 1 | 2021 | 399 | 0.140 |
Why?
| | Cell Polarity | 1 | 2017 | 17 | 0.140 |
Why?
| | Interleukin-4 | 1 | 2017 | 44 | 0.140 |
Why?
| | DNA Repair | 2 | 2019 | 196 | 0.140 |
Why?
| | Adult | 4 | 2021 | 14170 | 0.140 |
Why?
| | Adolescent | 2 | 2021 | 6737 | 0.140 |
Why?
| | Mice, Knockout | 1 | 2020 | 910 | 0.140 |
Why?
| | Protein Kinase C | 1 | 2017 | 70 | 0.140 |
Why?
| | Treatment Outcome | 2 | 2020 | 5486 | 0.140 |
Why?
| | Remission Induction | 1 | 2018 | 219 | 0.140 |
Why?
| | Gastrula | 1 | 2017 | 2 | 0.140 |
Why?
| | Fetal Proteins | 1 | 2017 | 5 | 0.140 |
Why?
| | Cell Survival | 2 | 2019 | 602 | 0.140 |
Why?
| | T-Box Domain Proteins | 1 | 2017 | 14 | 0.140 |
Why?
| | Morphogenesis | 1 | 2017 | 18 | 0.130 |
Why?
| | Proto-Oncogene Proteins c-akt | 2 | 2015 | 172 | 0.130 |
Why?
| | Macrophage Colony-Stimulating Factor | 1 | 2016 | 11 | 0.130 |
Why?
| | Arteries | 1 | 2017 | 94 | 0.130 |
Why?
| | Adenocarcinoma | 1 | 2020 | 404 | 0.130 |
Why?
| | STAT3 Transcription Factor | 1 | 2016 | 87 | 0.130 |
Why?
| | Cell Dedifferentiation | 1 | 2016 | 9 | 0.130 |
Why?
| | Fetus | 1 | 2017 | 195 | 0.120 |
Why?
| | Neoplasm Invasiveness | 1 | 2016 | 278 | 0.120 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2016 | 58 | 0.120 |
Why?
| | Transplantation, Autologous | 1 | 2018 | 488 | 0.120 |
Why?
| | Placenta | 1 | 2017 | 153 | 0.120 |
Why?
| | Carcinoma, Ductal, Breast | 1 | 2016 | 89 | 0.120 |
Why?
| | Tumor Stem Cell Assay | 1 | 2015 | 17 | 0.120 |
Why?
| | Anticholesteremic Agents | 1 | 2015 | 32 | 0.120 |
Why?
| | Neoplasm Metastasis | 1 | 2015 | 239 | 0.120 |
Why?
| | Measles Vaccine | 1 | 2014 | 5 | 0.120 |
Why?
| | Measles | 1 | 2014 | 8 | 0.110 |
Why?
| | Dyslipidemias | 1 | 2015 | 43 | 0.110 |
Why?
| | Vitamin A Deficiency | 1 | 2014 | 7 | 0.110 |
Why?
| | Lung Neoplasms | 1 | 2021 | 634 | 0.110 |
Why?
| | Vitamin A | 1 | 2014 | 17 | 0.110 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2015 | 107 | 0.110 |
Why?
| | Immunization Programs | 1 | 2014 | 23 | 0.110 |
Why?
| | Cholesterol | 1 | 2015 | 157 | 0.110 |
Why?
| | Regression Analysis | 1 | 2015 | 403 | 0.110 |
Why?
| | Receptor, IGF Type 1 | 1 | 2012 | 22 | 0.100 |
Why?
| | Receptor, Insulin | 1 | 2012 | 37 | 0.100 |
Why?
| | src-Family Kinases | 1 | 2012 | 34 | 0.100 |
Why?
| | Brain Neoplasms | 1 | 2016 | 290 | 0.100 |
Why?
| | Health Promotion | 1 | 2014 | 268 | 0.090 |
Why?
| | Infant | 2 | 2018 | 3720 | 0.090 |
Why?
| | Bone Diseases | 1 | 2012 | 95 | 0.090 |
Why?
| | Time Factors | 1 | 2016 | 3000 | 0.080 |
Why?
| | Prostatic Neoplasms | 1 | 2012 | 400 | 0.080 |
Why?
| | Apoptosis | 1 | 2012 | 1121 | 0.070 |
Why?
| | United States | 1 | 2017 | 5227 | 0.060 |
Why?
| | Protein Kinase Inhibitors | 2 | 2019 | 228 | 0.050 |
Why?
| | Neoplasm Grading | 1 | 2020 | 126 | 0.040 |
Why?
| | Sexual Behavior | 1 | 2021 | 127 | 0.040 |
Why?
| | Carboplatin | 1 | 2019 | 57 | 0.040 |
Why?
| | Papillomaviridae | 1 | 2019 | 105 | 0.040 |
Why?
| | Chemoradiotherapy | 1 | 2019 | 50 | 0.040 |
Why?
| | Immunotherapy | 1 | 2021 | 244 | 0.040 |
Why?
| | MAP Kinase Signaling System | 1 | 2019 | 127 | 0.040 |
Why?
| | Radiotherapy | 1 | 2019 | 129 | 0.040 |
Why?
| | Chemokine CCL22 | 1 | 2017 | 2 | 0.040 |
Why?
| | src Homology Domains | 1 | 2017 | 7 | 0.040 |
Why?
| | Phosphopeptides | 1 | 2017 | 7 | 0.040 |
Why?
| | Mannose-Binding Lectins | 1 | 2017 | 8 | 0.040 |
Why?
| | Clinical Competence | 1 | 2021 | 404 | 0.040 |
Why?
| | Biomimetic Materials | 1 | 2017 | 11 | 0.040 |
Why?
| | Enzyme Induction | 1 | 2017 | 77 | 0.040 |
Why?
| | Lectins, C-Type | 1 | 2017 | 31 | 0.040 |
Why?
| | Fibronectins | 1 | 2017 | 37 | 0.040 |
Why?
| | Molecular Mimicry | 1 | 2017 | 36 | 0.040 |
Why?
| | Cisplatin | 1 | 2019 | 285 | 0.040 |
Why?
| | Genetic Markers | 1 | 2017 | 109 | 0.030 |
Why?
| | Papillomavirus Infections | 1 | 2019 | 172 | 0.030 |
Why?
| | Allantois | 1 | 2017 | 1 | 0.030 |
Why?
| | Primitive Streak | 1 | 2017 | 1 | 0.030 |
Why?
| | Yolk Sac | 1 | 2017 | 8 | 0.030 |
Why?
| | Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2017 | 10 | 0.030 |
Why?
| | Umbilical Arteries | 1 | 2017 | 23 | 0.030 |
Why?
| | RNA, Small Interfering | 1 | 2017 | 218 | 0.030 |
Why?
| | Receptors, Cell Surface | 1 | 2017 | 113 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2019 | 600 | 0.030 |
Why?
| | Pentose Phosphate Pathway | 1 | 2016 | 2 | 0.030 |
Why?
| | Glucosephosphate Dehydrogenase | 1 | 2016 | 6 | 0.030 |
Why?
| | Gene Knockdown Techniques | 1 | 2016 | 110 | 0.030 |
Why?
| | Cadherins | 1 | 2016 | 63 | 0.030 |
Why?
| | Receptor, erbB-2 | 1 | 2016 | 80 | 0.030 |
Why?
| | Endothelium, Vascular | 1 | 2017 | 258 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2016 | 464 | 0.030 |
Why?
| | Sierra Leone | 1 | 2014 | 2 | 0.030 |
Why?
| | Maternal Welfare | 1 | 2014 | 10 | 0.030 |
Why?
| | Phenotype | 1 | 2017 | 800 | 0.030 |
Why?
| | Child Welfare | 1 | 2014 | 53 | 0.030 |
Why?
| | Cluster Analysis | 1 | 2014 | 233 | 0.030 |
Why?
| | Models, Biological | 1 | 2017 | 741 | 0.030 |
Why?
| | Information Dissemination | 1 | 2014 | 86 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2016 | 952 | 0.030 |
Why?
| | Immunoprecipitation | 1 | 2012 | 57 | 0.030 |
Why?
| | Triazines | 1 | 2012 | 26 | 0.030 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2012 | 237 | 0.020 |
Why?
| | Tumor Cells, Cultured | 1 | 2012 | 448 | 0.020 |
Why?
| | Pyrazoles | 1 | 2012 | 114 | 0.020 |
Why?
| | Drug Therapy, Combination | 1 | 2012 | 400 | 0.020 |
Why?
| | Blotting, Western | 1 | 2012 | 593 | 0.020 |
Why?
| | Pyrimidines | 1 | 2012 | 200 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2016 | 1486 | 0.020 |
Why?
| | Dietary Supplements | 1 | 2014 | 465 | 0.020 |
Why?
| | Pregnancy | 1 | 2017 | 2679 | 0.020 |
Why?
| | Infant, Newborn | 1 | 2014 | 2891 | 0.020 |
Why?
| | Child, Preschool | 1 | 2014 | 4062 | 0.020 |
Why?
|
|
Wolfe's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|